Multivessel Disease (MVD): 60 Second Insights
Published: 08 March 2018
-
Views:
2113
-
Likes:
7
-
Views:
2113
-
Likes:
7
-
Up Next -
52sPart 10 | Session 2 Simon Walsh
-
50sPart 10 | Session 3 Paul Knaapen
-
1m 14sPart 10 | Session 4 Colin Berry
-
43sPart 11 | Session 1 Keith Oldroyd
-
39sPart 11 | Session 2 Simon Walsh
-
57sPart 11 | Session 3 Paul Knaapen
-
19sPart 11 | Session 4 Colin Berry
-
57sPart 1 | Session 1 Keith Oldroyd Keith G Oldroyd
-
1m 7sPart 1 | Session 2 Simon Walsh Simon J Walsh
-
1m 8sPart 1 | Session 3 Paul Knaapen Paul Knaapen
-
53sPart 1 | Session 4 Colin Berry Colin Berry
-
51sPart 2 | Session 1 Keith Oldroyd Keith G Oldroyd
-
57sPart 2 | Session 2 Simon Walsh Simon J Walsh
-
1m 15sPart 2 | Session 3 Paul Knaapen Paul Knaapen
-
1m 10sPart 2 | Session 4 Colin Berry Colin Berry
-
43sPart 3 | Session 1 Keith Oldroyd Keith G Oldroyd
-
1m 14sPart 3 | Session 2 Simon Walsh Simon J Walsh
-
43sPart 3 | Session 3 Paul Knaapen Paul Knaapen
-
45sPart 3 | Session 4 Colin Berry Colin Berry
-
49sPart 4 | Session 1 Keith Oldroyd Keith G Oldroyd
-
1m 4sPart 4 | Session 2 Simon Walsh Simon J Walsh
-
1m 4sPart 4 | Session 3 Paul Knaapen Paul Knaapen
-
1m 12sPart 4 | Session 4 Colin Berry Colin Berry
-
59sPart 5 | Session 1 Keith Oldroyd Keith G Oldroyd
-
1m 7sPart 5 | Session 2 Simon Walsh Simon J Walsh
-
48sPart 5 | Session 3 Paul Knaapen Paul Knaapen
-
42sPart 5 | Session 4 Colin Berry Colin Berry
-
56sPart 6 | Session 1 Keith Oldroyd Keith G Oldroyd
-
1m 5sPart 6 | Session 2 Simon Walsh Simon J Walsh
-
1m 3sPart 6 | Session 3 Paul Knaapen Paul Knaapen
-
49sPart 6 | Session 4 Colin Berry Colin Berry
-
46sPart 7 | Session 1 Keith Oldroyd Keith G Oldroyd
-
52sPart 7 | Session 2 Simon Walsh Simon J Walsh
-
37sPart 7 | Session 3 Paul Knaapen Paul Knaapen
-
21sPart 7 | Session 4 Colin Berry Colin Berry
-
32sPart 8 | Session 1 Keith Oldroyd Keith G Oldroyd
-
35sPart 8 | Session 2 Simon Walsh Simon J Walsh
-
39sPart 8 | Session 3 Paul Knaapen Paul Knaapen
-
8sPart 8 | Session 4 Colin Berry Colin Berry
-
54sPart 9 | Session 1 Keith Oldroyd Keith G Oldroyd
-
1m 1sPart 9 | Session 2 Simon Walsh Simon J Walsh
-
58sPart 9 | Session 3 Paul Knaapen Paul Knaapen
-
1m 8sPart 9 | Session 4 Colin Berry Colin Berry
Overview
A short series of 60-second insight videos on Multivessel Disease (MVD).
More from this programme
Part 1
How do manage patients with multi-vessel disease during PPCI?
Part 2
Do you think we should be doing multi-vessel revascularisation instead of CABG? If so, in which cases?
Part 3
Do you prefer Clopidogrel, Ticagrelor or Prasugrel?
Part 4
Do you have any concerns giving adenosine during PPCI or would your prefer and adenosine-free technique?
Part 5
Do you believe registry (i.e. culprit only) or RCT data (treat all vessels)?
Part 6
Do you believe coronary physiology has a role in non-culprit PPCI decision-making?
Part 7
Are you using G2B3A inhibitors like ReoPro?
Part 8
Are you using Bivalirudin or Heparin?
Part 9
What trials best support the use of MVD PCI?
Part 10
Should we balloon acutely and then returning to stent the following morning?
Part 11
Should PPCI be performed at large surgical centres only?
Faculty Biographies
Keith G Oldroyd
Clinical Director of Cardiology
Professor Keith G Oldroyd MBChB; MD(Hons); FRCP(Glasg); FSCAI is a Consultant Interventional Cardiologist at the West of Scotland Regional Heart and Lung Centre in the Golden Jubilee National Hospital. He holds a personal chair within the Institute of Cardiovascular and Medical Sciences, University of Glasgow. He qualified in medicine from the University of Aberdeen in 1982.
In 2007 he became the first Clinical Director of Cardiology at the newly created West of Scotland Regional Heart and Lung Centre. From 2011-2014 he was also Director of R&D and currently he leads on CV research for NHS Scotland. His own research interests include the clinical and experimental assessment of novel drug eluting stents and the use of invasive physiological indices of stenosis severity to guide decision making in the cath lab. He has been a principal investigator in several international trials including FAME, FAME 2, PRAMI and LEADERS FREE, all of which have been published in…